| الوصف: |
// Jung-Min Lee 1 , John L. Hays 2 , Victoria L. Chiou 1 , Christina M. Annunziata 1 , Elizabeth M. Swisher 3 , Maria I. Harrell 3 , Minshu Yu 1 , Nicolas Gordon 1 , Tristan M. Sissung 4 , Jiuping Ji 5 , William D. Figg 4 , Lori Minasian 1 , Stanley Lipkowitz 1 , Bradford J. Wood 6 , James Doroshow 7 and Elise C. Kohn 1 1 Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 2 Division of Medical Oncology, Department of Internal Medicine, The James Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA 3 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA 4 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 5 National Clinical Target Validation Laboratory, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA 6 Center for Interventional Oncology, Radiology, and Imaging Sciences, Clinical Center and National Cancer Institute, NIH, Bethesda, MD, USA 7 Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD, USA Correspondence to: Jung-Min Lee, email: // Keywords : triple negative breast cancer, olaparib, carboplatin Received : July 27, 2016 Accepted : March 13, 2017 Published : March 25, 2017 Abstract PURPOSE: To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC).EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients with no germline BRCA mutation or with BRCAPro scores |
